HW201877 enantiomer is the enantiomer of HW201877 and is 15-hydroxyprostaglandin dehydrogenase ( 15-PGDH ) inhibitor with an IC50 of 12.2 nM. HW201877 enantiomer can be used for the research of inflammatory bowel disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease [1].
In Vitro, HW201877 enantiomer (Compound 25 A) exhibits an IC50 of 12.2 nM against 15-PGDH[1]. HW201877 enantiomer dose not elevate prostaglandin E2 (PGE2) levels in A549 cells[1].
References:
[1]. Li Q, et al. Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration. J Med Chem. 2025;68(13):14099-14113.
In Vitro, HW201877 enantiomer (Compound 25 A) exhibits an IC50 of 12.2 nM against 15-PGDH[1]. HW201877 enantiomer dose not elevate prostaglandin E2 (PGE2) levels in A549 cells[1].
References:
[1]. Li Q, et al. Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration. J Med Chem. 2025;68(13):14099-14113.